NASDAQ:NAGE Niagen Bioscience Q3 2026 Earnings Results & Report $1.82 -0.06 (-2.94%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Niagen Bioscience met analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.01 versus the -$0.01 consensus estimate, while revenue was $27.19 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market Closes Niagen Bioscience EPS ResultsActual EPS-$0.01Consensus EPS -$0.01Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersNiagen Bioscience Revenue ResultsActual Revenue$27.19 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Niagen Bioscience Q3 2026 Earnings FAQ Did Niagen Bioscience beat earnings estimates for Q3 2026? Niagen Bioscience (NASDAQ:NAGE) reported earnings of -$0.01 per share for Q3 2026, matching the consensus estimate of -$0.01. The report was announced on Wednesday, November 4, 2026. What was Niagen Bioscience's revenue for Q3 2026? Niagen Bioscience reported revenue of $27.19 million for Q3 2026. Niagen Bioscience Earnings HeadlinesNiagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on AgingNovember 16, 2026 | marketscreener.comMNiagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on AgingNovember 16, 2026 | businesswire.comEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.November 20 at 1:00 AM | Pennie Financial (Ad)Niagen Bioscience, Inc. (NASDAQ:NAGE) Stock Now Rated "Buy" by Wall Street BrokeragesNovember 13, 2026 | americanbankingnews.comNiagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ PlusNovember 12, 2026 | businesswire.comHead to Head Survey: Beauty Health (NASDAQ:SKIN) versus Niagen Bioscience (NASDAQ:NAGE)November 12, 2026 | americanbankingnews.comSee More Niagen Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email. Email Address About Niagen BioscienceNiagen Bioscience (NASDAQ:NAGE) develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels. Rob Fried is the company’s chief executive officer.View Niagen Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.